Protagonist Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Protagonist Therapeutics generated cash of -$70,236,000, which is more than the previous year. Cash used in financing activities reached the amount of $170,477,000 last year. Net change in cash is therefore $60,983,000.
Cash Flow
| 2014 | -7.74M | -299K | 9.00M |
|---|---|---|---|
| 2015 | -14.38M | -8.26M | 17.41M |
| 2016 | -29.97M | -59.32M | 106.30M |
| 2017 | 3.87M | 15.82M | 65.55M |
| 2018 | -49.94M | 2.21M | 24.11M |
| 2019 | -41.52M | -53.71M | 46.03M |
| 2020 | -72.48M | -90.96M | 247.62M |
| 2021 | -107.86M | -15.86M | 129.92M |
| 2022 | -108.13M | 91.46M | 18.83M |
| 2023 | -70.23M | -39.25M | 170.47M |
PTGX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 125.96M | 123.89M | 117.81M | 33.46M | 82.69M | 106.48M | 21.09M | 4.05M | 9.32M | 8.46M |
Operating activities | ||||||||||
Net income | -78.95M | -127.39M | -125.55M | -66.15M | -77.18M | -38.92M | -36.95M | -37.17M | -14.85M | -11.07M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.31M | 3.36M | 2.77M | 2.56M | 2.49M | 527K | 406K | 317K | 247K | 258K |
Stock-based compensation expense | 29.29M | 24.20M | 16.39M | 7.89M | 8.35M | 0 | 4.24M | 2.13M | 99K | 42K |
| Deferred income tax benefit | 29.29M | 24.20M | 16.39M | 7.89M | 8.35M | 0 | 4.24M | 2.13M | 99K | 42K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 4.24M | -915K | 3.33M | -757K | -2.77M | -1.81M | 0 | -192K | 0 |
Inventories | 0 | -4.24M | 915K | -3.33M | 757K | 3.85M | 5.53M | 0 | 0 | 0 |
Accounts payable | -2.86M | 2.04M | -1.39M | 309K | -3M | 4.43M | 91K | -115K | 898K | 179K |
Cash generated by operating activities | -70.23M | -108.13M | -107.86M | -72.48M | -41.52M | -49.94M | 3.87M | -29.97M | -14.38M | -7.74M |
Investing activities | ||||||||||
Purchases Of Investments | -191.04M | -214.87M | -286.58M | -280.02M | -166.93M | -71.06M | -39.54M | -73.16M | -7.86M | 0 |
Investments In Property Plant And Equipment | -609K | -795K | -1.10M | -471K | -967K | -486K | -666K | -379K | -399K | -299K |
Acquisitions Net | 0 | -91.46M | 14.75M | 90.49M | 52.74M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -39.25M | 91.46M | -15.86M | -90.96M | -53.71M | 2.21M | 15.82M | -59.32M | -8.26M | -299K |
Financing activities | ||||||||||
Common Stock Issued | 132.1M | 14.55M | 130.11M | 255.36M | 34.49M | 23.18M | 64.54M | 83.64M | 17.41M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -189K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -10.52M | 9.76M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 170.47M | 18.83M | 129.92M | 247.62M | 46.03M | 24.11M | 65.55M | 106.30M | 17.41M | 9.00M |
Net Change In Cash | 60.98M | 2.07M | 6.07M | 84.35M | -49.22M | -23.79M | 85.39M | 17.02M | -5.26M | 864K |
Cash at end of period | 186.95M | 125.96M | 123.89M | 117.81M | 33.46M | 82.69M | 106.48M | 21.08M | 4.05M | 9.32M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |